)
Shares of Natco Pharma has rallied 7% to Rs 2,196, extending its previous day’s 15% surge on the BSE after the company said it has received the approval for the generic anti-hepatitis C medicine sofosbuvir tablets of 400 mg from the Drugs Controller General-India (DCGI).
Today, the stock opened at Rs 2,080 and hit a fresh record high of Rs 2,264 on BSE. The trading volumes on the counter more than doubled with a combined 526,473 shares changed hands on the BSE and NSE till 1027 hours.
The stock of pharmaceutical company rose for a sixth straight session after the company signed a non-exclusive licensing agreement with Gilead Sciences to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries. It rallied nearly 50% from Rs 1,492 on March 3, 2015 compared with 2.5% fall in the S&P BSE Sensex.
Meanwhile, Dilip S Shanghvi, the promoter of Sun Pharmaceutical Industries hold 3.46% stake in Natco Pharma as on December 31, 2014, the shareholding pattern data shows.
Today, the stock opened at Rs 2,080 and hit a fresh record high of Rs 2,264 on BSE. The trading volumes on the counter more than doubled with a combined 526,473 shares changed hands on the BSE and NSE till 1027 hours.
The stock of pharmaceutical company rose for a sixth straight session after the company signed a non-exclusive licensing agreement with Gilead Sciences to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries. It rallied nearly 50% from Rs 1,492 on March 3, 2015 compared with 2.5% fall in the S&P BSE Sensex.
Meanwhile, Dilip S Shanghvi, the promoter of Sun Pharmaceutical Industries hold 3.46% stake in Natco Pharma as on December 31, 2014, the shareholding pattern data shows.
